Acid reflux drug for heart attack recovery
Treatments studied
Part of Digestive system clinical trials.
This trial tests if a newer acid-reducing drug is better than standard care for preventing stomach problems in people who recently had a heart attack and a stent placed. It could help those who need stomach protection while on blood thinners.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You had a heart attack (STEMI or NSTEMI) recently.
- You had a stent or drug-coated balloon placed in your heart artery.
- You are willing to take a study medication for stomach acid.
- You do not have active stomach bleeding or a history of allergy to the study drugs.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new stomach acid medicine (Zastaprazan) affects how well clopidogrel works in heart patients who have had a stent placed. It aims to help people who need both clopidogrel and a stomach acid drug after a procedure.
This trial tests a new medicine, zastaprazan, to see if it can prevent stomach or intestinal bleeding in people who have had a stroke or mini-stroke and are taking blood thinners or anti-clotting drugs. It might help protect your stomach while you're on these medications.
This trial compares a potassium-competitive acid blocker to a proton pump inhibitor to help prevent stomach or intestinal bleeding in people at high risk who take blood-thinning medicines. It may help reduce dangerous GI bleeding while you stay on heart/stroke medicines.
This study looks at whether a type of stomach acid medication called PCAB can help people who have had a heart stent and take blood thinners. It checks if PCAB is safe and reduces stomach bleeding.
This trial tests a treatment for nighttime heartburn caused by GERD, a condition where stomach acid damages the esophagus. It is for adults who have had nighttime heartburn for more than 3 months and have been diagnosed with erosive GERD.
This trial tests whether fexuprazan can prevent upper gastrointestinal bleeding in people at high risk who need two antiplatelet drugs for at least 6 months after a heart stent. If you are on dual antiplatelet therapy after a stent and have risk factors like older age, low weight, or history of ulcers, this study may help protect your stomach.
Hear when a new Gastrointestinal Bleeding trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.